Drug firm Zydus Cadila today said it has received approval from the US health regulator to market Clobetasol Propionate ointment, used to treat a range of skin conditions, in the American market.
The company has received final approval from the US Food and Drug Administration (USFDA) to market its product, Zydus Cadila said in a statement.
The ointment will be manufactured at the company's Ahmedabad-based facility. The Zydus group has now more than 165 product approvals.
Stock of Cadila Healthcare, the listed entity of the Zydus group, was trading 0.32 per cent up at Rs 492.95 on the BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
